pharmanewsdaily
1509 posts
Amgen’s Repatha proves effective in major cardiovascular outcomes study
Amgen Inc. has achieved a significant milestone with its cholesterol-lowering injection, Repatha (evolocumab), demonstrating a 20% reduction in…
March 18, 2017
TiGenix reports success for AlloCSC-01 in Phase I/II heart failure study
TiGenix, a Belgium-based biopharmaceutical company, has announced promising results from its Phase I/II study assessing the safety and…
March 13, 2017
FDA clears Servier and Pfizer for clinical development of UCART19 for acute lymphoblastic leukemia
Servier and Pfizer Inc. have received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration…
March 12, 2017
EC approves Actelion’s Ledaga for treatment of cutaneous T-cell lymphoma
The European Commission (EC) has granted marketing authorization to Actelion Pharmaceuticals for its innovative Ledaga Chlormethine Gel 160…
March 11, 2017
AstraZeneca and Sanofi Pasteur forge €615m alliance to develop infant respiratory drug MEDI8897
AstraZeneca’s biotech arm, MedImmune, and Sanofi Pasteur, the vaccines division of French pharmaceutical giant Sanofi, have entered into…
March 6, 2017
FDA approves Serenity Pharmaceuticals’ Noctiva for nocturnal polyuria
Serenity Pharmaceuticals has received U.S. Food and Drug Administration (FDA) approval for Noctiva (desmopressin acetate), a nasal spray…
March 5, 2017
Sanofi and Regeneron’s Dupixent shows promising results in Phase 3 eczema trial
Sanofi and Regeneron Pharmaceuticals have achieved a significant milestone with their jointly developed eczema drug, Dupixent (dupilumab), meeting…
March 5, 2017
FDA approves CeloNova Cobra PzF coronary stent system
The US Food and Drug Administration (FDA) has approved the Cobra PzF nanocoated coronary stent system developed by…
March 3, 2017
Roche’s Perjeta shows significant promise in phase 3 breast cancer trial
Roche has announced promising results from the APHINITY trial, a crucial Phase 3 study evaluating Perjeta (pertuzumab) in…
March 2, 2017
FDA approves Lexicon Pharmaceuticals’ Xermelo for carcinoid syndrome diarrhea
Lexicon Pharmaceuticals has received approval from the US Food and Drug Administration (FDA) for its oral drug Xermelo…
March 1, 2017